Article

WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human Study

2026-03-18

Abstract excerpt

<title>Abstract</title> KRAS G12D mutations occur in approximately 2–4% of patients with non-small cell lung cancer (NSCLC). GFH375, a compound that targets both “ON” (GTP-bound) and “OFF” (GDP-bound) states of the KRAS G12D proteins, was evaluated in a phase 1/2 study among patients with advanced solid tumors harboring KRAS G12D mutations. The objectives were to evalua...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7fba3e67-d94f-5e30-bb9b-90137bc61767
DOI: 10.21203/rs.3.rs-8540837/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human StudyDOI 10.21203/rs.3.rs-8540837/v1Read

WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human StudySemantic proximity Read

OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C MutationSemantic proximity Read

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.Semantic proximity Read

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read

Advances in the treatment of KRASG12C mutant non–small cell lung cancerSemantic proximity Read

KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.Semantic proximity Read

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.Semantic proximity Read

Current perspectives of KRAS in non-small cell lung cancer.Semantic proximity Read

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.Semantic proximity Read

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.Semantic proximity Read